Analyst Coverage

The following organisations provide research coverage on Pharmaxis: 

Bell Potter logo1

Bell Potter Securities Limited

Analyst: Tanushree Jain (tnjain@bellpotter.com.au)

Bell Potter initiated coverage on 8 December 2017.

For copies of current reports contact Bell Potter.

25 November 2019

Approaching key inflection points

16 August 2019

FY19 Audited Results - No material change

30 July 2019

Key catalysts coming up in FY20

24 June 2019

FDA Issues CRL on Bronchitol - approval now expected in early 2020

15 May 2019

Bronchitol gets positive recommendation from Adcom by a narrow majority

 

15 February 2019

Strong cash position and approaching key inflection points

30 April 2018

Interim data from Phase 1 LOXL-2 program strengthen partnering prospects

16 February 2018 1H18 Results - no material change from unaudited results released earlier
1 February 2018

Good clinical and partnering progress on LOXL-2 asset

11 January 2018

BI milestone strengthens balance sheet, LOXL-2 moves into the clinic

8 December 2017

Emerging as a key player in multi-billion dollar NASH market

Bioshares5

Bioshares

Editors: David Blake and Mark Pachacz (info@bioshares.com.au)

Read Bioshares most recent reports:

28 October 2019

PXS Completes Phase Ia Trial of PXS5505A

24 June 2019

Pharmaxis' Bronchitol Edges Closer to FDA Approval

13 May 2019

Pharmaxis Gains Positive Vote for Bronchitol in USA

29 April 2019

Pharmaxis Update

25 February 2019

Pharmaxis Tackles the Intractable

25 January 2019

Pharmaxis' LOXL2 Program Ready for a Deal

10 December 2018

Pharmaxis Investor Briefing Summary

12 October 2018

More Positive Phase I Data from LOXL2 Program

13 August 2018 Pharmaxis strengthens balance sheet ahead of LOXL2 licensing deal
20 July 2018 Interview with Dr Kathleen Metters
8 May 2018

Pharmaxis – a drug developer with a deal making record

5 February 2018 A busy year for Pharmaxis – multiple trial readouts ahead
8 September 2017

Pharmaxis – Boehringer selects diabetic retinopathy as second indication

4 September 2017

Pharmaxis' partner starts phase II NASH trial

24 March 2017

Three share price drivers for Pharmaxis

28 October 2016 Pharmaxis. All attention on NASH for Pharmaxis